Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;46(2):163-170.
doi: 10.15537/smj.2025.46.2.20240620.

GLP-1RA and SGLT2i utilization in people with type 2 diabetes with atherosclerotic cardiovascular disease (ASCVD) or at high risk of ASCVD in the Gulf Region: Results from the PACT-MEA studys

Waleed A Al-Dahi  1 , Saeed H Khalaf  1 , Dalal A AlRomaihi  1 , Naji M Alamuddin  1 , Hessa M Al Kandari  1 , Doaa K Abdalla  1 , Hanan Y Alfadehla  1 , Amin A Jayyousi  1 , Mashhood A Siddique  1 , Usama A AlAlami  1 , Guruprasad C Subbarao  1 , Shashikanth J Chetty  1 , Jehan A Abdulla  1
Affiliations

GLP-1RA and SGLT2i utilization in people with type 2 diabetes with atherosclerotic cardiovascular disease (ASCVD) or at high risk of ASCVD in the Gulf Region: Results from the PACT-MEA studys

Waleed A Al-Dahi et al. Saudi Med J. 2025 Feb.

Abstract

Objectives: To provide insights into the real-world usage of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) among individuals with type 2 diabetes (T2D) from Bahrain, Kuwait, and Qatar who either had established atherosclerotic cardiovascular disease (eASCVD) or were at high risk of developing ASCVD.

Methods: This study of 1062 adults diagnosed with T2D from Bahrain, Kuwait, and Qatar is a sub-analysis within the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients with Type 2 Diabetes across Countries in the Middle East and Africa (PACT-MEA) study, a noninterventional, cross-sectional study. Participants were recruited from 13 primary or secondary care facilities between March and August 2022. Medical records of participants were reviewed to extract relevant data, including demographic characteristics, eASCVD status, ASCVD risk and glucose-lowering treatment. Appropriate descriptive and inferential statistical tests were performed.

Results: Among T2D participants with eASCVD, a significantly higher proportion (41.3%) received SGLT2i compared to GLP-1RA (10.5%, p<0.001). There were notable variations in GLP-1RA/SGLT2i utilization across countries (p<0.001): being lowest in Bahrain (2.3%/18.0%), 26.9%/58.2% in Kuwait and 10.5%/67.1% in Qatar. The use of both medications was significantly higher in individuals with body mass index (BMI) ≥30 kg/m2 (p<0.05).

Conclusion: Despite these cardioprotective agents being recommended by guidelines, the study findings suggest a suboptimal use of GLP-1RA and SGLT2i in a real-world setting.

Keywords: Diabetes mellitus; Middle East; atherosclerosis; cardiovascular diseases; hypoglycemic agents; type 2.

PubMed Disclaimer

Figures

Figure 1
Figure 1
- Considerations for antihyperglycemic treatments according to the study physicians surveyed in the Gulf Region (n=105)
See this image and copyright information in PMC

References

    1. American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. Diabetes care 2019; 42: S103-S123. - PubMed
    1. Pearson-Stuttard J, Bennett J, Cheng YJ, Vamos EP, Cross AJ, Ezzati M, et al. . Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol 2021; 9: 165-173. - PMC - PubMed
    1. International Diabetes Federation (IDF). IDF Diabetes Atlas 10th ed. Brussels (Belgium): IDF; 2021.
    1. Verma S, Alamuddin N, Alawadi F, Alkandari H, Almahmeed W, Assaad-Khalil SH, et al. . Prevalence of Diabetes and Cardiovascular Risk in the Middle East and Africa: Primary Results of the PACT-MEA Study. Circulation 2023; 147: 1251-1255. - PMC - PubMed
    1. Alqadasi ET, Chamroonsawasdi K, Saejeng K, Nagi MA. Burden of non-communicable diseases in Health Council of Gulf Cooperation (GCC) countries. J Taibah Univ Med Sci 2024; 19: 877-884. - PMC - PubMed

Substances